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ust a Spoonful of Sugar*
oy C. Ziegelstein, MD, FACP,
ara D. Miller, BA
altimore, Maryland
hich one of us hasn’t cried to mom or dad, pinched his or
er nose, and taken medicine under protest. Although
ubble gum and fruit flavorings have made it easier, encour-
ging adherence to treatment regimens is a challenging task
ot only for parents but also for physicians. What we need
s “just a spoonful of sugar” to help the medicine go down.
Ensuring adherence is particularly important when treat-
ng a patient who is depressed. Medical students are taught
he mnemonic “SIGECAPS” to remember the cardinal
eatures of major depression (sleep, interest, guilt, energy,
oncentration, appetite, psychomotor, suicidal). The “I” and
he “C” indicate that depressed patients exhibit diminished
interest” and “concentration.” No surprise, then, that pa-
ients with depression have difficulty adhering to treatments
hat might favorably impact their health. DiMatteo et al. (1)
uggest that 3 factors make it more difficult for depressed
atients to adhere to medical treatment regimens: 1) feel-
ngs of hopelessness that make it harder to believe that
reatments will help; 2) social isolation that limits interac-
ion with people who might offer support in adhering to
edications; and 3) cognitive difficulties that make it hard
o remember to take medications.
See page 2218
Beneficial treatments have been defined for both primary
nd secondary prevention of heart disease, but a substantial
ap exists between the favorable results reported in clinical
rials and those achieved in clinical practice. Recognizing
hat part of this gap relates to patients’ failure to adhere to
edical therapy, the American Heart Association convened
n expert panel on the topic of adherence almost a decade
go (2). And, noting how depression negatively impacts
dherence, Fox (3) asked a very relevant question at that
ime: “Would antidepressant treatment make a difference to
ompliance—and mortality?”
The observation by Rieckmann et al. (4) in this issue of
he Journal that patients with acute coronary syndrome
ACS) who also have depression have difficulty with adher-
nce to medications is not by itself new or novel. It has been
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, Johns Hopkins University School of Medicine,m
altimore, Maryland. Dr. Ziegelstein is supported by the Miller Family Scholar
rogram.nown for several years now that depression at the time of
n acute coronary event is a “litmus test” for poor adherence
uring the next few months (5). Yet until now, there has not
een any evidence that improvement in depression might be
ssociated with improved adherence.
Rieckmann et al. (4) monitored the adherence to daily
spirin therapy of 172 patients after a hospitalization for an
CS using an electronic medication monitoring system.
atients with the most severe depressive symptoms in the
ospital demonstrated the poorest adherence. Of patients
ithout depression, 15% did not take at least 80% of their
aily aspirin. By comparison, 29% of mildly depressed
atients and 37% of moderately-to-severely depressed pa-
ients did not adhere to aspirin therapy. Patients whose
epression improved in the first month after the ACS
emonstrated improvements in adherence rates in the sub-
equent 2 months.
So why should cardiologists care? Acute myocardial
nfarction practice guidelines recommend that the psycho-
ocial status of patients be evaluated, “including inquiries
egarding symptoms of depression” (6). Despite this recom-
endation, formal screening for depression generally is not
art of routine care in the ACS setting. In the absence of
ormal screening, underrecognition of depressive illness is
ommon (7). Perhaps the observation that when depression
mproves adherence does as well, and the possibility that
his might improve cardiovascular outcomes, will more
trongly motivate the cardiology community not only to
ecommend depression screening in practice guidelines, but
lso to incorporate it as part of routine care.
For more than a decade, investigators have fairly consis-
ently demonstrated a relationship between depression and
ncreased mortality after an ACS (8). Plausible mechanistic
inks to explain such a relationship have been documented
n patients with depression, including increased platelet
ctivation (9), increased inflammation (10), autonomic dys-
unction that may predispose to ventricular arrhythmias
11), and poor adherence to medical treatment regimens (5).
lthough studies have also shown that selective serotonin
euptake inhibitors decrease platelet activation (12), inflam-
ation (13), and cardiac autonomic dysfunction (14), no
tudy has shown that selective serotonin reuptake inhibitors
mprove adherence. The findings by Rieckmann et al. (4)
uggest that a study examining this question would be an
mportant and logical next step.
So how important is it that patients adhere to what we
ecommend? It is now a well-known but still fascinating
bservation that adherence per se, whether to active treat-
ent or to a “sugar pill,” may have beneficial health effects.
recent meta-analysis of 21 studies, including 8 studies
ith placebo arms, confirmed that good adherence—
hether to beneficial drug therapy or to placebo—is asso-
iated with lower mortality (15). “A spoonful of sugar” may
ot just help the medicine go down, it may also help
ortality go down. In several studies in the cardiovascular
l
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Editorial Comment December 5, 2006:2223–4iterature, patients who adhered to placebo had a lower
ortality than patients who did not. In the Coronary Drug
roject Research Group study (16), BHAT (the Beta-
locker Heart Attack Trial) (17), CAMIAT (the Canadian
miodarone Myocardial Infarction Arrhythmia Trial) (18),
nd CHARM (the Candesartan in Heart failure: Assess-
ent of Reduction in Mortality and morbidity) trial (19),
ood adherence was associated with almost identically lower
ortality in the active treatment and placebo groups.
erhaps the good adherers in the placebo arms of these trials
ho faithfully took “a spoonful of sugar” when recom-
ended also exhibited other positive health behaviors that
mproved their outcome. Or, perhaps one’s attitude toward
reatment regimens is of critical importance in determining
utcome. Regardless of the mechanism, adherence is im-
ortant, and the findings by Rieckmann et al. (4) provide yet
nother reason why depression screening should be incor-
orated into routine ACS care.
eprint requests and correspondence: Dr. Roy C. Ziegelstein,
epartment of Medicine, B-1-North, Johns Hopkins Bayview
edical Center, 4940 Eastern Avenue, Baltimore, Maryland
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